Skip to main content
. 2020 Mar 12;46(4):557–562. doi: 10.1590/S1677-5538.IBJU.2019.0154

Table 1. Clinical characteristics of the patients in both groups.

  Group I (n=159) Group II (n=93) p
Age (years) 61.82 (±7.39) 62.28 (±6.16) 0.612
Body mass index (BMI) (kg/m2) 26.10 (22.80-27.70) 26.10 (22.80-28.30) 0.966
Total prostate volume (mm3) 51.62 (34.00-71.73) 50.00 (40.00-60.00) 0.627
Serum PSA level (ng/dL) 6.99 (5.01-10.10) 8.01 (5.05-9.12) 0.615
Number of biopsy cores (n) 16.0 (15.0-19.0) 12.0 (11.0-12.0) <0.001
Malignancy detection rate (n, %) 70/159 (44.0%) 24/93 (25.8%) 0.004

PSA = Prostate specific antigen